| Edwin Moses (CEO)
Wim Ottevaere (CFO)|
ABLX (EBR) € 11.56 +0.04 (+0.39%)28 Feb, 3:59 PM GMT+1 - Disclaimer
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies.
In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2M was provided by Gimv.
In July 2015 Merck & Co. and Ablynx expanded their 18 month old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for Ablynx. In 2015, the Novo Nordisk announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.